Regulatory News
Tuesday, April 26, 2016
BRIEF-Summit's IND cleared by FDA
* Summit's IND cleared by FDA allowing expansion of phaseout
dmd, a phase 2 clinical trial of ezutromid (smt c1100), into the
us
Source text for Eikon:
Further company coverage:
(Bengaluru...
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment